The US FDA has approved Merck & Co. Inc.’s Zinplava (bezlotoxumab) for reducing the recurrence of Clostridium difficile infection (CDI) in patients 18 years of age or older who are receiving antibacterial drug treatment of CDI and are at high risk for CDI recurrence.
The product is an antibody therapy targeted against a toxin produced by the bacterium, known as toxin B, that causes...





